Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04537377 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease
A Phase 1 study of Wilson's Disease, sponsored by Vivet Therapeutics SAS.
- Active
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
- 10
- Study locations
NCT04537377 is a Phase 1 study of Wilson's Disease that is active but no longer recruiting, run by Vivet Therapeutics SAS. The registered enrollment target is 4 participants. The trial reports 10 study locations across 8 states.
The verdict
NCT04537377, a Phase 1 study of Wilson's Disease, is active but no longer recruiting, sponsored by Vivet Therapeutics SAS.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
- 10
- Study locations
Study Summary
The objectives of this clinical trial are to assess, for up to 5 years, the safety, tolerability and pharmacological activity of a single ascending doses of VTX-801, a gene therapy, administered intravenously (IV) to adult patients with Wilson's Disease prior to and following background WD therapy withdrawal.
Conditions Studied
Interventions
- GENETIC VTX-801
Study Locations (10)
Other
- Aarhus University Hospital - Aarhus
- University Hospital Essen - Essen
- Universitätsklinikum Tübingen (UKT) - Tübingen
California
- UC Davis Medical Center - Sacramento
Connecticut
- Yale University School of Medecine - New Haven
Florida
- Advent Health - Orlando
Michigan
- University of Michigan Health System - Ann Arbor
North Carolina
- Wake Forest School of Medicine - Winston-Salem
Texas
- University of Texas Southwestern Medical Center - Dallas
Surrey
- Royal Surrey County Hospital - Guildford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2021-09-03 |
| Est. Completion | 2029-06-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04537377
The ClinicalTrials.gov registry entry for NCT04537377 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vivet Therapeutics SAS, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Wilson's Disease appearing as the primary indexed condition, and to 1 intervention - of which VTX-801 is the first listed.
NCT04537377 reports 10 study locations spanning 8 distinct geographic areas - top geographies include Other, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT04537377 about?
NCT04537377 is a clinical study titled "A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease". The objectives of this clinical trial are to assess, for up to 5 years, the safety, tolerability and pharmacological activity of a single ascending doses of VTX-801, a gene therapy, administered intravenously (IV) to adult patients with Wilson's Disease prior to and following background WD therapy w...
What is the current status of trial NCT04537377?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2021-09-03. Estimated completion is 2029-06-18.
What conditions does trial NCT04537377 study?
This clinical trial studies the following conditions: Wilson's Disease.
What interventions are being tested in trial NCT04537377?
The interventions under investigation include: VTX-801 (GENETIC).
Who is sponsoring clinical trial NCT04537377?
This trial is sponsored by Vivet Therapeutics SAS, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04537377 being conducted?
This trial has 10 study locations across California, Connecticut, Florida, Michigan, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.